Oncology (all articles)
RCT: Tislelizumab vs. chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma.
3 May, 2022 | 10:36h | UTC
Commentary on Twitter
In the phase III RATIONALE-302 trial of tislelizumab vs chemotherapy as 2nd-line therapy for advanced-stage ESCC, mOS was 8.6 vs 6.3 months (HR 0.70; P=0.0001), rising to 10.3 vs 6.8 months for those with a PD-L1 tumour area positivity score >10%: https://t.co/CNxads2Kn2 #esocsm
— NatureRevClinOncol (@NatRevClinOncol) April 27, 2022
RCT: Digital remote monitoring plus usual care vs. usual care in patients treated with oral anticancer agents.
2 May, 2022 | 00:37h | UTCDigital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial – Nature Medicine (if the link is paywalled, try this one)
Commentary on Twitter
A phase 3 clinical trial evaluating the impact of a digital nurse navigator-led system in patients receiving oral #cancer treatment shows that remote monitoring with a smartphone results in improved patient experience & optimizes resources @GustaveRoussy https://t.co/N8fEXb00r7
— Nature Medicine (@NatureMedicine) April 26, 2022
RCT: Efficiency of electronic health record assessment of patient-reported outcomes after cancer immunotherapy.
2 May, 2022 | 00:36h | UTCInvited Commentary: An Assistive Electronic Patient-Reported Outcome Monitoring Intervention for Management of Immune-Related Toxic Effects—Moving Toward Efficiency and Scale – JAMA Network Open
Commentary on Twitter
This RCT aimed to compare the efficiency between ePRO and traditional follow up models in cancer immunotherapy among 278 patients from 28 hospitals, finding that an ePRO model can improve safety & QOL, and is less time consuming. https://t.co/KtpcNz0keb pic.twitter.com/EsmNyTkdfB
— JAMA Network Open (@JAMANetworkOpen) March 31, 2022
Clinical management of metastatic colorectal cancer in the era of precision medicine.
1 May, 2022 | 23:27h | UTC
RCT: Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy.
1 May, 2022 | 23:20h | UTC
RCT: Digital breast tomosynthesis plus synthesized mammography versus digital screening mammography for the detection of invasive breast cancer.
1 May, 2022 | 23:14h | UTCDigital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial – The Lancet Oncology (link to abstract – $ for full-text)
Guideline: Clinical utility of multigene profiling assays in early-stage invasive breast cancer.
1 May, 2022 | 23:06h | UTC
Evidence-based approach to the treatment of esophagogastric junction tumors.
29 Apr, 2022 | 08:12h | UTC
NCCN Guideline: Gastric Cancer.
29 Apr, 2022 | 08:05h | UTC
Guideline: Management of small renal masses.
28 Apr, 2022 | 10:36h | UTCSee also: Summary of Recommendations
Consensus Statement: Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis syndromes.
28 Apr, 2022 | 10:35h | UTC
Review: Germline testing and genetic counselling in prostate cancer.
28 Apr, 2022 | 08:11h | UTCGermline testing and genetic counselling in prostate cancer – Nature Reviews Urology (if the link is paywalled, try this one at PMC)
Duration of treatment in oncology clinical trials: does the duration change when the same drug moves from the experimental arm to the control arm?
28 Apr, 2022 | 08:03h | UTC
Checkpoint inhibitor–associated arthritis: a systematic review of case reports and case series.
28 Apr, 2022 | 07:58h | UTC
RCT: Effect of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone on progression-free survival among patients with newly diagnosed metastatic nasopharyngeal carcinoma who had received induction chemotherapy.
27 Apr, 2022 | 07:44h | UTCEffect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Randomized trial of efficacy and safety of capecitabine maintenance therapy in metastatic nasopharyngeal carcinoma demonstrates that capecitabine maintenance therapy improved survival & was associated with manageable toxicities. https://t.co/Ay2WZ7ZuCN pic.twitter.com/sZJ6qfzCOY
— JAMA Oncology (@JAMAOnc) February 17, 2022
Endocrine therapy response and 21-Gene expression assay for therapy guidance in HR+/HER2– early breast cancer.
27 Apr, 2022 | 07:41h | UTCEndocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Gene Score, Endocrine Response Can Guide Early Breast Cancer Therapy – MedPage Today (free registration required)
M-A: Intensification of systemic therapy in addition to definitive local treatment in nonmetastatic unfavorable prostate cancer.
26 Apr, 2022 | 07:51h | UTC
Critical analysis of the updated guidelines for management of gallbladder polyps.
26 Apr, 2022 | 07:41h | UTCCritical Analysis of the Updated Guidelines for Management of Gallbladder Polyps – Annals of Surgical Oncology (if the link is paywalled, try this one)
A comprehensive and comparative review of global gastric cancer treatment guidelines.
26 Apr, 2022 | 07:39h | UTC
RCT: Segmentectomy resulted in better outcomes than lobectomy in small-sized peripheral non-small-cell lung cancer.
25 Apr, 2022 | 01:03h | UTCSegmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
Consensus Statement: Management of patients with advanced prostate cancer.
25 Apr, 2022 | 00:50h | UTC
Commentary on Twitter
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021https://t.co/GjTGPx8IbN@APCCC_Lugano @Silke_Gillessen @AOmlin @AarmstrongDuke @piet_ost @Prof_IanD @DrSpratticus @charlesryanmd @Tilki_De @declangmurphy pic.twitter.com/FU0Fbjf8WZ
— European Urology (@EUplatinum) April 22, 2022
Guidelines: Cutaneous lymphomas.
25 Apr, 2022 | 00:38h | UTC
Perspective: Delivering precision oncology to patients with cancer.
25 Apr, 2022 | 00:13h | UTCDelivering precision oncology to patients with cancer – Nature Medicine (free for a limited period)
Commentary on Twitter
A Perspective in @NatureMedicine outlines the major challenges to the implementation of precision oncology and discusses critical steps toward resolving them. https://t.co/7l3WmFffn3 pic.twitter.com/oxFMZGZunf
— Nature Portfolio (@NaturePortfolio) April 24, 2022
Phase 2 RCT: Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer.
24 Apr, 2022 | 23:53h | UTC
Commentary on Twitter
In the phase II NEOBLADE trial in 120 pts with locally advanced MIBC, addition of the multitarget RTK TKI nindetanib to neoadjuvant chemotherapy did not significantly improve the pCR rate: 37% versus 32% (OR 1.25, 70% CI 0.84–1.87; P=0.28): https://t.co/m9NXouhOcZ #blcsm
— NatureRevClinOncol (@NatRevClinOncol) April 22, 2022
RCT: Pembrolizumab vs. chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
24 Apr, 2022 | 23:52h | UTCPembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study – The Lancet Oncology (link to abstract – $ for full-text)